Efficacy, Tolerability, and Safety of Toludesvenlafaxine for the Treatment of Major Depressive Disorder—A Narrative Review

The estimated rate of treatment-resistant major depressive disorder (TRD) remains higher than 30%, even after the discovery of multiple classes of antidepressants in the last 7 decades. Toludesvenlafaxine (ansofaxine, LY03005, or LPM570065) is a first-in-class triple monoaminergic reuptake inhibitor...

Descripción completa

Detalles Bibliográficos
Autor principal: Vasiliu, Octavian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051807/
https://www.ncbi.nlm.nih.gov/pubmed/36986510
http://dx.doi.org/10.3390/ph16030411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051807/
https://www.ncbi.nlm.nih.gov/pubmed/36986510
http://dx.doi.org/10.3390/ph16030411

Ejemplares similares